Literature DB >> 32932327

Clinical Course of COVID-19 Infection in Patients Urgently Operated of Cardiac Surgical Procedures.

Andrea Garatti1,2, Serenella Castelvecchio1, Andrea Daprati1, Raffaella Molfetta1, Marianna Volpe1, Carlo De Vincentiis1, Alessandro Parolari3, Lorenzo Menicanti1.   

Abstract

OBJECTIVE: The aim of this study was to describe the clinical course of a consecutive series of patients operated of urgent cardiac surgery during COVID-19 outbreak.
BACKGROUND: In Italy, COVID outbreak has mostly occurred in the metropolitan area of Milan, and in the surrounding region of Lombardy, and previously "conventional" hospitals were converted into COVID spokes to increase ICU beds availability, and to allow only urgent CS procedures.
METHODS: Among urgent CS patients (left main stenosis with unstable angina, acute endocarditis, valvular regurgitation with impending heart failure), 10 patients (mean age = 57 ± 9 years), despite a negative admission triage, developed COVID-pneumonia postoperatively, at a median of 7 days after CS.
RESULTS: Patients showed typical lymphopenia, higher prothrombotic profile, and higher markers of inflammation (ferritin and interleukin-6 values). At the zenith of pulmonary distress, patients presented with severe hypoxia (median PaO2/FIO2 ratio = 116), requiring advanced noninvasive ventilation (Venturi mask and continuous positive airway pressure) in the majority of cases. All patients were treated with hydroxychloroquine, azithromycin, and low-molecular-weight heparin at anticoagulant dose. Overall in-hospital mortality was 10% (1/10), peaking 25% in patients who developed COVID pneumonia immediately after CS. The remaining patients, with late infection, were all discharged home without oxygen support, at a median of 25 days after symptom onset.
CONCLUSIONS: As postoperative mortality in case of COVID pneumonia is not negligible, meticulous rules (precise triage, safe hospital path, high level of protection for health-care teams, prompt diagnosis of suspicious symptoms) should be strictly followed in patients undergoing CS during COVID pandemic. The role of therapies alternative to CS should be further assessed.

Entities:  

Mesh:

Year:  2020        PMID: 32932327     DOI: 10.1097/SLA.0000000000004393

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  4 in total

1.  Detection of residual pulmonary alterations with lung ultrasound and effects on postoperative pulmonary complications for patients with asymptomatic SARS-CoV-2 infection undergoing surgeries.

Authors:  Susana González-Suárez; Antonio Barbara Ferreras; Melissa Caicedo Toro; Macarena Aznar de Legarra
Journal:  BMC Anesthesiol       Date:  2022-06-16       Impact factor: 2.376

2.  Prognostic value of SARS-CoV-2 on patients undergoing cardiac surgery.

Authors:  Giorgia Bonalumi; Alberto Pilozzi Casado; Alessandro Barbone; Andrea Garatti; Andrea Colli; Ilaria Giambuzzi; Lucia Torracca; Giacomo Ravenni; Gianluca Folesani; Giacomo Murara; Antonio Pantaleo; Marco Picichè; Emmanuel Villa; Francesco Ferraro; Igor Vendramin; Ugolino Livi; Andrea Montalto; Francesco Musumeci; Vincenzo Tarzia; Cinzia Trumello; Michele De Bonis; Vito Margari; Domenico Paparella; Antonio Salsano; Francesco Santini; Salvatore Nicolardi; Francesco Patanè; Liborio Mammana; Erik Cura Stura; Mauro Rinaldi; Francesco Massi; Michele Triggiani; Valentina Grazioli; Laura Giroletti; Antonino Rubino; Marisa De Feo; Andrea Audo; Tommaso Regesta; Fabio Barili; Gino Gerosa; Michele Di Mauro; Alessandro Parolari
Journal:  J Card Surg       Date:  2021-10-30       Impact factor: 1.620

Review 3.  Infective endocarditis and COVID -19 coinfection: An updated review.

Authors:  Anu George; Sai Vikram Alampoondi Venkataramanan; Kevin John John; Ajay Kumar Mishra
Journal:  Acta Biomed       Date:  2022-03-14

4.  A Systematic Review and Meta-Analysis of Inpatient Mortality Associated With Nosocomial and Community COVID-19 Exposes the Vulnerability of Immunosuppressed Adults.

Authors:  Mark J Ponsford; Tom J C Ward; Simon M Stoneham; Clare M Dallimore; Davina Sham; Khalid Osman; Simon M Barry; Stephen Jolles; Ian R Humphreys; Daniel Farewell
Journal:  Front Immunol       Date:  2021-10-06       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.